DA-R-EPOCH regimen: Difference between revisions
(←Redirected page to DA-EPOCH regimen) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}}; {{AE}} {{AV}} | |||
{{SK}}DA-EPOCH-R; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Regimen; EPOCH-R regimen; EPOCH-R; EPOCH-R regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Rituximab Regimen | |||
==Overview== | |||
{{PAGENAME}} refers to a chemotherapy regimen consisting of Dose-adjusted [[etoposide]], [[prednisone]], [[vincristine|vincristine (Oncovin)]] ,[[Cyclophosphamide]] and [[doxorubicin|doxorubicin (hydroxydaunorubicin hycrochloride)]], which may be used in combination with [[rituximab]] (R-EPOCH) for the treatment of various aggressive B cell and T cell [[non-Hodgkin lymphomas]]<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63779 }}</ref> and HIV-associated B-cell [[non-Hodgkin lymphoma]]<ref name="pmid20023215">{{cite journal| author=Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF et al.| title=Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. | journal=Blood | year= 2010 | volume= 115 | issue= 15 | pages= 3008-16 | pmid=20023215 | doi=10.1182/blood-2009-08-231613 | pmc=PMC2858478 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20023215 }} </ref> | |||
==Regimen== | |||
{{chemo|DA|Dose-adjusted}} | |||
{{chemo|R|Rituximab}} | |||
{{chemo|E|Etoposide}} | |||
{{chemo|P|Prednisone}} | |||
{{chemo|O|vincristine (Oncovin)}} | |||
{{chemo|C|Cyclophosphamide}} | |||
{{chemo|H|doxorubicin (Hydroxydaunorubicin hycrochloride)}} | |||
==Indications== | |||
*[[Non-Hodgkin lymphomas|Primary mediastinal(thymic)B-cell lymphoma]]<ref name="pmid25596693">{{cite journal| author=Higashide Y, Hayashi T, Hirayama D, Wagatsuma K, Aoki Y, Maruyama Y et al.| title=[A Case of Primary Mediastinal(Thymic)B-Cell Lymphoma Successfully Treated with the DA-EPOCH-RR egimen]. | journal=Gan To Kagaku Ryoho | year= 2015 | volume= 42 | issue= 1 | pages= 119-22 | pmid=25596693 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25596693 }} </ref> | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Chemotherapy regimens]] | |||
Revision as of 18:35, 31 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:DA-EPOCH-R; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Regimen; EPOCH-R regimen; EPOCH-R; EPOCH-R regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Rituximab Regimen
Overview
DA-R-EPOCH regimen refers to a chemotherapy regimen consisting of Dose-adjusted etoposide, prednisone, vincristine (Oncovin) ,Cyclophosphamide and doxorubicin (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas[1] and HIV-associated B-cell non-Hodgkin lymphoma[2]
Regimen
DADose-adjusted
RRituximab
EEtoposide
PPrednisone
Ovincristine (Oncovin)
CCyclophosphamide
Hdoxorubicin (Hydroxydaunorubicin hycrochloride)
Indications
References
- ↑ "NCI Thesaurus".
- ↑ Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF; et al. (2010). "Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma". Blood. 115 (15): 3008–16. doi:10.1182/blood-2009-08-231613. PMC 2858478. PMID 20023215.
- ↑ Higashide Y, Hayashi T, Hirayama D, Wagatsuma K, Aoki Y, Maruyama Y; et al. (2015). "[A Case of Primary Mediastinal(Thymic)B-Cell Lymphoma Successfully Treated with the DA-EPOCH-RR egimen]". Gan To Kagaku Ryoho. 42 (1): 119–22. PMID 25596693.